Treatment of Chronic Stroke With AMES + EMG Biofeedback — AMES  

Stroke Clinical Trial

Official title: Treatment of Chronic Stroke With AMES + EMG Biofeedback

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if individuals who had a stroke more than one year before entering the study and who remain unable to open their affected hand are better able to sense and move their affected arm after 10-15 weeks of treatment with a new robotic therapy device (the AMES device) and EMG biofeedback.

Clinical Trial Description

Over the last 20 years, the discovery of cortical plasticity in the adult human brain has led to the development of new therapies to rehabilitate stroke survivors whose recovery of motor function has stalled with conventional therapeutic methodology. However, the efficacy of these new therapies appears to be limited to relatively high-functioning chronic stroke patients. A therapeutic approach that may be efficacious in restoring functional movement to low-functioning chronic stroke patients is "AMES," which stands for Assisted Movement with Enhanced Sensation. Despite the efficacy of AMES in restoring movement to low-functioning hemiparetic stroke patients, those with plegia at a joint tend not to recover movement in the plegic direction with AMES treatment or with other rehabilitation therapies. The objective of this study is to determine if AMES treatment in combination with biofeedback can be helpful in restoring functional movement to plegic stroke patients. ;

Related Conditions & MeSH terms

• Cerebrovascular Accident
• Paresis
• Plegia
• Stroke

• NCT number: NCT01116544
• Study type: Interventional
• Source: AMES Technology
• Status: Completed
• Phase: N/A
• Start date: September 21, 2007
• Completion date: February 28, 2011